IntelGenx Technologies (OTCMKTS:IGXT) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Monday.
Several other equities analysts have also recently issued reports on the company. Aegis reiterated a “buy” rating on shares of IntelGenx Technologies in a research report on Monday, January 29th. Zacks Investment Research upgraded IntelGenx Technologies from a “sell” rating to a “hold” rating in a research report on Wednesday, February 7th. Finally, HC Wainwright set a $2.00 price target on IntelGenx Technologies and gave the company a “buy” rating in a research report on Wednesday, December 6th.
Shares of IGXT stock traded down $0.01 during mid-day trading on Monday, hitting $0.70. 132,664 shares of the stock traded hands, compared to its average volume of 86,766. IntelGenx Technologies has a twelve month low of $0.60 and a twelve month high of $1.09. The stock has a market cap of $47.41, a PE ratio of -17.38 and a beta of 0.70. The company has a debt-to-equity ratio of 1.53, a quick ratio of 2.65 and a current ratio of 2.65.
IntelGenx Technologies Corp. is a drug delivery company focusing on the development of orally administered drug delivery products based on its oral drug delivery technologies. The Company is a provider of product development services for the pharmaceutical industry, including the branded and generic pharmaceutical markets.
Receive News & Ratings for IntelGenx Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelGenx Technologies and related companies with MarketBeat.com's FREE daily email newsletter.